The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Vasograin Plus represents a major advancement in the treatment of migraine
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The submission is supported by results from the Phase 3b APEX study
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
